Effect of prebiotics, probiotics, and symbiotics on molecular markers of inflammation in obesity
e202212090
Keywords:
Prebiotics, Probiotics, Inflammation, ObesityAbstract
BACKGROUND // Obesity is an inflammatory disease that is widely distributed in the world’s population and is related to the leading causes of death. The use of prebiotics and probiotics can be an alternative treatment against obesity. Although there have been found physiological and biochemical effects of its use, the molecular mechanism remains unclear. The present review analyzed articles that suggested the activation of pathways related to the metabolism of the fatty acids, as well as the impact on anti-inflammatory mechanisms, as part of the mechanism of action of prebiotics and probiotics, to know therefore the possible pathways activated by the prebiotics and probiotics.
METHODS // Exhaustive research was made on articles included in the period 2005-2021 related to the effect of prebiotics and probiotics in obesity, inflammatory diseases, and metabolic diseases. Identifying an effect on anti-inflammatory cytokines and PPAR modulation, with a consequent decrease in inflammation and fat degradation.
RESULTS // A total of sixty-three articles were obtained, which were classified as basic information on molecular markers of obesity, the effect of prebiotics and probiotics in obesity, and articles related to anti-inflammatory effects and fatty acid metabolism observed in obesity and other inflammatory diseases.
CONCLUSIONS // The effect of prebiotics and probiotics in obesity can be linked to the anti-inflammatory mechanism produced, and this effect leads to an increase in the expression of genes related to fatty acid metabolism.
Downloads
References
1. Organización Mundial de la Salud. Sobrepeso y Obesidad. 2016. Nota descriptiva Nº 113. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/
2. García D, Catellanos G, Cedeño R, Benet M, Ramírez I. Tejido Adiposo como glándula endócrina. Revista Finlay. 2011;1:2-20p. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/39/1209
3. Goyal R, Faizy A, Siddiqui S, Shingai M. Evaluation of TNF-α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects. N Am J Med Sci. 2012; 4:180-184. doi: https://doi.org/10.4103/1947-2714.94944
4. Cox A, West N, Cripps A. Obesity, inflammation and the gut microbiota. Lancet Diabetes and Endocrinol. 2014;3:207-215. DOI: https://doi.org/10.1016/S2213-8587(14)70134-2
5. Wang T. TNF-alpha inhibition of adiponectin expression by targeting PPAR-gamma and C/EBP in adipocytes. Tesis de Maestría. Louisiana State University and Agricultural and Mechanical College. United States. 2009.
6. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener J, van Rooijen N, Staels, B, Kersten S, Müller M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology. 2010; 51: 511-522. DOI: https://doi.org/10.1002/hep.23337
7. Kersten S. Integrated physiology and systems biology of PPAR-α. Mol Metab. 2014; 3: 354-371. DOI: https://doi.org/10.1016/j.molmet.2014.02.002
8. Konig B, Koch A, Spielmann J, Hilgenfeld C, Stangl G, Eder K. Activation of PPARα lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochem Pharmacol. 2007; 73:574-585. DOI: https://doi.org/10.1016/j.bcp.2006.10.027
9. Kapadia R, Yi J, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008; 1:1813-1826. DOI: https://doi.org/10.2741/2802
10. Majdalawieh A, Ro HS. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal. 2010; 8:1-17. DOI: https://doi.org/10.1621/nrs.08004
11. Charles B, Doumatey A, Huang H, Zhou J, Chen G, Shriner D et al. The roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-Americans. J Clin Endocrinol and Metab. 2011; 92: 2018-2022p. DOI: https://doi.org/10.1210/jc.2011-1497
12. León-Cabrera S, Arana-Lechuga Y, Esqueda-León E, Terán-Pérez G, González-Chavez A, Escobedo G et al. Reduced Systemic Levels of IL-10 Are Associated with the Severity of Obstructive Sleep Apnea and Insulin Resistance in Morbidly Obese Humans. Mediators Inflamm. 2015:493409. DOI: https://doi.org/10.1155/2015/493409
13. Flint HJ. Obesity and the gut microbiota. J Clin Gastroenterol. 2011 Nov;45 Suppl:S128-32. doi: https://doi.org/10.1097/MCG.0b013e31821f44c4
14. Turnbaugh P, Ley R, Mahowland M, Magrini V, Mardis, E, Gordon J. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2007; 444:1026-1031. https://doi.org/10.1038/nature05414
15. Ley R, Turnbaugh P, Klein S. Gordon J. Microbial Ecology: Human gut microbes associated with obesity. Nature. 2007; 444:1022-1023. DOI: https://doi.org/10.1038/4441022a
16. Turnbaugh P, Hamady M, Yatsunenko T, Cantarel B, Duncan A, Ley R et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457:480-484. DOI: https://doi.org/10.1038/nature07540
17. Wu G, Chen J, Hoffmann C, Bittinger K, Chen Y, Keilbaugh A et al. Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes. Science. 2011; 334:105-108. DOI: https://doi.org/10.1126/science.1208344
18. Banks A, McAllister F, Camporez J, Zushin P, Jurczak M, Laznik-Bogoslavski D et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature. 2015; 517:391-395 DOI: https://doi.org/10.1038/nature13887
19. Muccioli G, Naslain D, Bäckhed F, Reigstad C, Lambert D, Delzenne N et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010; 6(392). DOI: https://doi.org/10.1038/msb.2010.46
20. Farías M, Silva C. Rozowski J. Microbiota Intestinal: Rol en Obesidad. Rev Chil Nutr. 2011. 38:228-233. DOI: https://doi.org/10.4067/S0717-75182011000200013
21. Meador B, Krzyszton C, Johnson R, Huey K. Effects of IL-10 and age on IL-6, IL-1beta, and TNF-alpha responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J Appl Physiol. 2008; 104:991-997. DOI: https://doi.org/10.1152/japplphysiol.01079.2007
22. Dasu M, Ramirez S, Isseroff R. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci (Lond). 2012; 122:203-214. DOI: https://doi.org/10.1042/CS20110357
23. Souza C, Teiceira A, Biondo L, Silveira L, Calder S, Rosa J. Palmitoleic acid reduces the inflammation in LPS-stimulated macrophages by inhibition of NFκB, independently of PPARs. Clin Exp Pharmacol Phisiol. 2017; 44: 566-575 DOI: https://doi.org/10.1111/1440-1681.12736
24. Starus D, Glass C. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007; 28:551-558. DOI: https://doi.org/10.1016/j.it.2007.09.003
25. Zizzo G, Cohen P. The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization. J Inflamm (Lond). 2015; 12:1-16. DOI: https://doi.org/10.1186/s12950-015-0081-4
26. Blanquicett C, Bum-Yong K, Ritzenthaler J, Jones D, Hart C. Oxidative Stress Modulates PPARγ in Vascular Endothelial Cells. Free Radic Biol Med. 2010; 48:1618-1625 DOI: https://doi.org/10.1016/j.freeradbiomed.2010.03.007
27. Nagy Z, Czimmerer Z, Szanto A, Nagy L. Pro-inflammatory cytokines negatively regulate PPARγ mediated gene expression in both human and murine macrophages via multiple mechanisms. Immunobiology. 2013; 218:1336-1344 DOI: https://doi.org/10.1016/j.imbio.2013.06.011
28. Para el tratamiento integral del sobrepeso y la obesidad. NORMA Oficial Mexicana NOM-008-SSA3-2010. Diario Oficial de la Federación, 4 de agosto del 2010.
29. Bengmark S, Gil A. Bioecological and nutritional control of disease: prebiotics, probiotics and synbiotics. Nutr Hosp. 2006; 21:72-84.
30. Anggeraini AS, Massi MN, Hamid F, Ahmad A, As’ad S, Bukhari A. Effects of synbiotic supplement on body weight and fasting blood glucose levels in obesity: A randomized placebo-controlled trial. Ann Med Surg (Lond). 2021; 68:102548. DOI: https://doi.org/10.1016/j.amsu.2021.102548
31. Brighenti F. Dietary fructans and serum triacylglycerols: a meta-analysis of randomized controlled trials. J Nutr. 2007; 137:2552-2556. DOI: https://doi.org/10.1093/jn/137.11.2552S
32. Dahinya D, Puniya M, Shandilya U, Dhewa T, Kumar N, Kumar S et al. Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. Front Microbiol. 2017; 8:563. DOI: https://doi.org/10.3389/fmicb.2017.00563
33. Alard J, Lehrter V, Rhimi M, Mangin I, Peucelle V, Abraham A et al. Beneficial metabolic effects of selected probiotics on diet-induced obesity and insulin resistance in mice are associated with improvement of dysbiotic gut microbiota. Environ Microbiol. 2016; 18:1484–1497. DOI: https://doi.org/10.1111/1462-2920.13181
34. Den Besten G, van Eunen K, Groen A, Venema K, Reijngoud D, Bakker B. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013; 54:2325-2340. DOI: https://doi.org/10.1194/jlr.R036012
35. Romeo J, Nova E, Warnberg J, Gómez S, Díaz L, Marcos A. Immunomodulatory effect of fibres, probiotics and synbiotics in different life-stages. Nutr Hosp. 2010; 25:341-349.
36. Rather S, Pothuraju R, Sharma R, De S, Mir N, Jangra S. Anti-obesity effect of feeding probiotic dahi containing Lactobacillus casei NCDC 19 in high fat diet-induced obese mice. Int. J. Dairy Technol. 2014; 67:504–509. DOI: https://doi.org/10.1111/1471-0307.12154
37. Kim K, Jeong J, Kim D. Lactobacillus brevis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-kB activation and gut microbial LPS production. J Funct Foods. 2015; 13:183–191. DOI: https://doi.org/10.1016/j.jff.2014.12.045
38. Park S, Ji Y, Jung H, Park H, Kang J, Choi S et al. Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol. 2017; 101:1605–1614. DOI: https://doi.org/10.1007/s00253-016-7953-2
39. Chichlowski M, De Lartigue G, German J, Raybould E, Mills A. Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J Pediatric Gastroenterol Nutr. 2012; 55:321-327. DOI: https://doi.org/10.1097/MPG.0b013e31824fb899
40. Suarez J. Microbiota autóctona, probióticos y prebióticos. Nutr Hosp. 2013; 28:38-41.
41. Yoda K, Sun X, Kawase M, Kubota A, Miyazawa K, Harata G et al. A combination of probiotics and whey proteins enhances anti-obesity effects of calcium and dairy products during nutritional energy restriction in aP2-agouti transgenic mice. Br J Nutr. 2015; 113:1689-1696. DOI: https://doi.org/10.1017/S0007114515000914
42. Mencarelli A, Distruitti E, Renga B, D’Amore C, Cipriani S, Palladino G et al. Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation. Plos One. 2011; 6(7). DOI: https://doi.org/10.1371/journal.pone.0022978
43. Eun C, Han D, Lee S, Jeon Y, Sohn J, Kim Y et al. Probiotics may reduce inflammation by enhancing peroxisome proliferator activated receptor gamma activation in HT-29 cells. Korean J Gastroenterol. 2007; 49(3). 139-146.
44. Bubnov R, Babenko L, Lazarenko L, Mokrozub V, Demchenko O, Nechypurenko O et al. Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. The EMPA J. 2017; 8:357-376. DOI: https://doi.org/10.1007/s13167-017-0117-3
45. Li Z, Jin H, Oh S, Ji G. Anti-obese effects of two Lactobacilli and two Bifidobacteria on ICR mice fed on a high fat diet. Biochem Biophys Res Commun. 2016; 480:222-227. DOI: https://doi.org/10.1016/j.bbrc.2016.10.031
46. Kang J, Yun S, Park M, Park J, Jeong S, Park H. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One. 2013; 8(1). doi: https://doi.org/10.1371/journal.pone.0054617
47. Daniali M, Nikfar S, Abdollahi M. A brief overview on the use of probiotics to treat overweight and obese patients. Expert Rev Endocrinol Metab, 2020; 15, 1-4. DOI: https://doi.org/10.1080/17446651.2020.1719068
48. Walsh CJ, Healy S, O’Toole PW, Murphy EF, Cotter PD. The probiotic L. casei LC-XCALTM improves metabolic health in a diet-induced obesity mouse model without altering the microbiome. Gut Microbes, 2020; 12(1):1-17. DOI: https://doi.org/10.1080/19490976.2020.1747330
49. Chiou WC, Chang BH, Tien HH, Cai YL, Fan YC, Chen WJ et al. Synbiotic intervention with an adlay-based prebiotic and probiotics improved diet-induced metabolic disturbance in mice by modulation of the gut microbiota. Nutrients, 2021; 13:3161. DOI: https://doi.org/10.3390/nu13093161
50. Narala V, Adapala R, Suresh M, Brock T, Peters-Golden M, Reddy R. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem. 2010; 285:22067-22074. DOI: https://doi.org/10.1074/jbc.M109.085118
51. Poulsen L, Serisbaek M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin in Cell Dev Biol. 2012; 23: 631-639. DOI: https://doi.org/10.1016/j.semcdb.2012.01.003
52. Bougarne N, Paumelle R, Caron S, Hennuyer N, Mansouri R, Gervois P et al. PPAR-α blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc of Natl Acad Sci USA. 2009; 106(18). 7397-7402. DOI: https://doi.org/10.1073/pnas.0806742106
53. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation. Pulm Pharmacol Ther. 2008; 21(2). 324-330. DOI: https://doi.org/10.1016/j.pupt.2007.08.001
54. Hecker M, Behnk A, Morty R, Sommer N, Vadász I, Herold S et al. PPAR-α activation reduced LPS-induced inflammation in alveolar epithelial cells. Exp Lung Res. 2015; 41:393-403. DOI: https://doi.org/10.3109/01902148.2015.1046200
55. Shiomi Y, Yamauchi T, Iwabu M, Okada-Iwabu M, Nakayama R, Orikawa Y et al. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice. J Biol Chem. 2015; 290:14567-14581. doi: https://doi.org/10.1074/jbc.M114.622191
56. Huang W, Glass C. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler, Thromb Vasc Biol. 2010; 30:1542-1549. DOI: https://doi.org/10.1161/ATVBAHA.109.191189
57. Chandra M, Sumitra M, Panchatcharam M. PPARγ and Its Role in Cardiovascular Diseases. PPAR Research. 2017. 1-10p. doi: https://doi.org/10.1155/2017/6404638
58. Ketsawatsomkron P, Sigmund C. Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. Curr Opin Nephrol Hypertens. 2015; 24:123-130. DOI: https://doi.org/10.1097/MNH.0000000000000103
59. Kim S, Lee K, Park H, Park S. Min K, Jin S et al. Involvement of IL-10 in Peroxisome Proliferator Activated Receptor gamma Mediated Antiinflamatory response in Asthma. Mol Pharmacol. 2005; 68:1568-1575. DOI: https://doi.org/10.1124/mol.105.017160
60. Hong E, Ko H, Cho Y, Kim H, Ma Z, Yu T et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009; 58:2525-2535. doi: https://doi.org/10.2337/db08-1261
61. Klen J, Dolžan V. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. Int J Mol Sci. 2022; 23:3451. doi: https://doi.org/10.3390/ijms23073451
62. Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y et al. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne) 2018;9. doi: https://doi.org/10.3389/fendo.2018.00233
63. Tsai C-Y, Lu H-C, Chou Y-H, Liu P-Y, Chen H-Y, Huang M-C et al. Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Front Endocrinol (Lausanne) 2022;12. doi: https://doi.org/10.3389/fendo.2021.814770
Downloads
Published
How to Cite
License
Copyright (c) 2022 Brian Eduardo Rangel-Torres, Alejandra Rodríguez-Tadeo, Isui Abril García-Montoya, Florinda Jiménez-Vega
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
